BR112016030439A2 - ácidos nucléicos para o tratamento de alergias ao amendoim. - Google Patents

ácidos nucléicos para o tratamento de alergias ao amendoim.

Info

Publication number
BR112016030439A2
BR112016030439A2 BR112016030439A BR112016030439A BR112016030439A2 BR 112016030439 A2 BR112016030439 A2 BR 112016030439A2 BR 112016030439 A BR112016030439 A BR 112016030439A BR 112016030439 A BR112016030439 A BR 112016030439A BR 112016030439 A2 BR112016030439 A2 BR 112016030439A2
Authority
BR
Brazil
Prior art keywords
treatment
nucleic acids
peanut allergies
allergies
peanut
Prior art date
Application number
BR112016030439A
Other languages
English (en)
Portuguese (pt)
Inventor
Heiland Teri
Hearl William
Original Assignee
Immunomic Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomic Therapeutics Inc filed Critical Immunomic Therapeutics Inc
Publication of BR112016030439A2 publication Critical patent/BR112016030439A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112016030439A 2014-06-23 2015-06-23 ácidos nucléicos para o tratamento de alergias ao amendoim. BR112016030439A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462015981P 2014-06-23 2014-06-23
PCT/US2015/037240 WO2015200357A2 (en) 2014-06-23 2015-06-23 Nucleic acids for treatment of peanut allergies

Publications (1)

Publication Number Publication Date
BR112016030439A2 true BR112016030439A2 (pt) 2018-07-17

Family

ID=53546722

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016030439A BR112016030439A2 (pt) 2014-06-23 2015-06-23 ácidos nucléicos para o tratamento de alergias ao amendoim.

Country Status (9)

Country Link
US (2) US20170304432A1 (https=)
EP (1) EP3157558A2 (https=)
JP (1) JP2017521064A (https=)
KR (1) KR20170019457A (https=)
CN (1) CN106459994A (https=)
AU (2) AU2015280143A1 (https=)
BR (1) BR112016030439A2 (https=)
CA (1) CA2952726A1 (https=)
WO (1) WO2015200357A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11452774B2 (en) 2015-02-20 2022-09-27 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10166286B2 (en) 2015-02-20 2019-01-01 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10149904B2 (en) 2015-02-20 2018-12-11 The Board Of Trusteees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10143742B2 (en) 2015-02-20 2018-12-04 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
WO2017186808A1 (en) * 2016-04-27 2017-11-02 Allergy Therapeutics (Uk) Limited Treatment of peanut allergy
US11826423B2 (en) 2016-11-16 2023-11-28 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
IL270024B2 (en) * 2017-04-22 2025-04-01 Immunomic Therapeutics Inc LAMP structures and their use in vaccination
KR20200016224A (ko) 2017-05-02 2020-02-14 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 lamp (리소솜 연관 막 단백질) 구축물
WO2019018529A1 (en) 2017-07-18 2019-01-24 Before Brands, Inc. METHODS OF MAKING MIXED ALLERGEN COMPOSITIONS
US20210163957A1 (en) 2018-05-11 2021-06-03 Astellas Pharma Inc. Nucleic acid for treating mite allergy
JOP20200284A1 (ar) 2018-05-11 2020-11-09 Astellas Pharma Inc حمض نووي لعلاج حساسية القشريات
EP3793595A1 (en) 2018-05-15 2021-03-24 Immunomic Therapeutics, Inc. Improved lamp constructs comprising allergens
CN109115737B (zh) * 2018-07-27 2021-03-26 青岛大学 一种三螺旋pH生物传感器及其应用
AU2020213085A1 (en) 2019-01-23 2021-08-12 Société des Produits Nestlé S.A. Methods for making mixed allergen compositions
EP3938053A4 (en) * 2019-03-13 2023-03-22 Psomagen, Inc. EPITOP-BASED APPROACH TO ALLERGY TREATMENTS AND INHIBITORS FOR CROHN'S DISEASE
CN112225815A (zh) * 2020-09-30 2021-01-15 四川携光生物技术有限公司 一种牛奶、小麦、花生及大豆过敏原融合蛋白及其构建方法、应用
CN114438088B (zh) * 2020-11-03 2025-05-23 韩达 一种溶酶体靶向的核酸嵌合体的制备及应用
KR102527331B1 (ko) * 2020-11-10 2023-05-02 (주)프로테옴텍 밀가루 유래의 오메가-5-글리아딘의 신규 에피토프 중합체 및 이의 용도
WO2022099695A1 (en) * 2020-11-16 2022-05-19 Jiangsu Cell Tech Medical Research Institute Co., Ltd. Cd164 fusion and uses thereof
CN115057927B (zh) * 2022-05-30 2024-02-20 南开大学 一种花生过敏原Ara h1特异性纳米抗体及其应用
WO2025199077A1 (en) * 2024-03-19 2025-09-25 Modernatx, Inc. Tolerizing antigen specific immunotherapies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2130100A1 (en) * 1992-03-03 1993-09-16 Ian S. Trowbridge Receptor internalization signals
US20060251667A1 (en) * 2002-08-29 2006-11-09 Chua Kaw Y Recombinant nucleic acid useful for inducing protective immune response against allergens
AU2012382406B2 (en) * 2012-06-15 2017-12-07 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
US9774230B2 (en) * 2015-11-25 2017-09-26 Caterpillar Inc. Generator set having coupling member between flywheel and generator

Also Published As

Publication number Publication date
JP2017521064A (ja) 2017-08-03
KR20170019457A (ko) 2017-02-21
WO2015200357A2 (en) 2015-12-30
WO2015200357A3 (en) 2016-04-21
CN106459994A (zh) 2017-02-22
EP3157558A2 (en) 2017-04-26
AU2015280143A1 (en) 2017-01-05
AU2020204277A1 (en) 2020-07-16
US20170304432A1 (en) 2017-10-26
US20190298821A1 (en) 2019-10-03
CA2952726A1 (en) 2015-12-30

Similar Documents

Publication Publication Date Title
BR112016030439A2 (pt) ácidos nucléicos para o tratamento de alergias ao amendoim.
DK3234132T3 (da) Ligand-modificerede dobbeltstrengede nukleinsyrer
DK3433368T3 (da) Transreplikerende rna
MA42846A (fr) Identification universelle
PL3118311T3 (pl) Antysensowny kwas nukleinowy
IL249574B (en) Antisense nucleic acids
DK3981437T3 (da) Nukleinsyrevacciner
PT3785717T (pt) Métodos para o tratamento de infeções por coronaviridae
DK3234134T3 (da) Målrettet rna-redigering
DK3102669T3 (da) Forbedret bacillevært
FI20165606A7 (fi) Lämpökäsittely
DK3167044T3 (da) Mikrofluidindretning
PT3185957T (pt) Patisiran para utilização no tratamento de amoloidose mediada por transtirretina
EP3286549A4 (en) BIOSENSOR
EP3227659C0 (en) THAWING PROCESSES
DK3094731T3 (da) Saccharidmodificerede nukleinsyremolekyler
EP3156789C0 (en) BIOSENSOR
BR112016022976A2 (pt) Métodos para o tratamento de hcv
LT3183340T (lt) Termolabilios egzonukleazės
PL3408417T3 (pl) Sposób obróbki cieplnej
DK3119886T3 (da) Kopiantalsbevarende RNA-analysefremgangsmåde
EP3395436A4 (en) MICRO REACTOR
DK3307436T3 (da) Mikrofluidanordning
EP3387414A4 (en) BIOSENSOR
EP3371575A4 (en) BIOSENSOR

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notice of approval relating to section 229 industrial property law
B06U Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements